Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Conditions
SYSTEMIC REACTION
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Allergy
Interventions
Intradermal cat allergen challenge
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Conditions
Allergic Reactions
Interventions
Neffy, Adrenaline
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Glenview, Illinois + 3 more
Terminated Phase 1Phase 2 Interventional

Open-label Extension Study of ADP101

NCT05243719
Conditions
Food Allergy
Interventions
ADP101
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 57 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more
Conditions
Peanut Allergy
Interventions
DBV712 IHRP
Drug
Lead sponsor
DBV Technologies
Industry
Eligibility
12 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas • Aurora, Colorado
Conditions
Allergy, Asthma
Interventions
Glycerinated German cockroach allergenic extract, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cat Allergy, Cat Hypersensitivity
Interventions
AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Active, not recruiting No phase listed Observational

Food Oral Immunotherapy for Peanut Allergy

NCT04222491
Conditions
Peanut Allergy
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Food Allergy Peanut
Interventions
Peanut allergen
Biological
Lead sponsor
Scripps Health
Other
Eligibility
15 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Allergic Rhinitis
Interventions
Allergen Immunotherapy Extract, Allergen Immunotherapy Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1Phase 2 Interventional Results available

Biomarkers of Cockroach Sublingual Immunotherapy 2

NCT01380327
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Cockroach Sublingual Immunotherapy (SLIT) - Low Dose, Placebo, Cockroach Sublingual Immunotherapy (SLIT) - High Dose
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Completed No phase listed Observational

Mechanisms of Allergen Immunotherapy

NCT00001910
Conditions
Asthma, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Allergic Rhinitis
Interventions
Grass pollen extract, Placebo injection
Biological · Other
Lead sponsor
Amber Patterson
Other
Eligibility
15 Years to 24 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Conditions
Asthma
Interventions
House Dust Mite SLIT, High dose SLIT, Placebo SLIT
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Allergic Rhinitis
Interventions
Dupilumab, Timothy Grass SCIT, Placebo matching dupilumab, Placebo matching SCIT
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Los Angeles, California • Mountain View, California • Walnut Creek, California + 9 more
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Terminated Not applicable Interventional Results available

CBT-I for Cannabis Use

NCT02102230
Conditions
Marijuana Abuse, Sleep Initiation and Maintenance Disorders
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I), Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA), Desensitization Treatment for Insomnia
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions

NCT01878929
Conditions
Allergic Rhinitis, Asthma, Allergic Conjunctivitis
Interventions
Allergen(Tree, Grass, Weeds)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
South Euclid, Ohio
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 55 Years
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 53 more
Conditions
Anaphylaxis as a Result of Allergen or Venom Immunotherapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts